PLASMODIUM MOTILITY

Dissecting cGMP- and calcium-dependent signalling pathways that control gliding of a malaria zoite

Coordinatore	GENOME RESEARCH LIMITED    more  Organization address address: THE GIBBS BUILDING, EUSTON ROAD 215 city: LONDON postcode: NW1 2BE contact info Titolo: Mr. Nome: David Cognome: Davison Email: send email Telefono: +44 1223 834244 Fax: +44 1223 494919
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	179˙603 €
EC contributo	179˙603 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-IEF
Funding Scheme	MC-IEF
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-07-01   -   2013-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	GENOME RESEARCH LIMITED  Organization address address: THE GIBBS BUILDING, EUSTON ROAD 215 city: LONDON postcode: NW1 2BE contact info Titolo: Mr. Nome: David Cognome: Davison Email: send email Telefono: +44 1223 834244 Fax: +44 1223 494919	UK (LONDON)	coordinator	179˙603.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Malaria parasites critically depend on an unusual form of gliding motility to colonize their hosts and to invade cells. Transmission of malaria to the mosquito, for instance, relies on the ability of the motile zygote, the ookinete, to glide towards and invade the midgut epithelium. Results obtained in the host team have revealed a central role of cGMP- and calcium-dependent signalling in ookinete motility. Nevertheless, how these pathways control gliding is unknown. I therefore propose to combine real-time quantitative imaging approaches with molecular phenotyping of parasite phosphoproteins to identify and distinguish molecular targets of signalling through calcium and cGMP-dependent pathways in Plasmodium berghei ookinetes. For this purpose, I will use transgenic parasites in which cGMP- and/or calcium-dependent signalling pathways are either inactivated and/or deregulated. The impact of genetically inhibiting or over-stimulating specific protein kinases on motility will be analysed in an automated quantitative imaging assay, allowing signalling pathways to be linked with specific changes in motility phenotypes. I will then use shotgun phosphoproteomics on enriched populations of selected mutants to identify candidate substrates. Phenotyping of stage-specific mutants in candidate substrates will allow the molecular targets of signalling cascades to be verified.'